Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,GNFT,-16953000,45750200,11115000,,-24239500,,-24105000,3872000,1205000,-13916500,-13916500,134500,-2964500,,,,-134500,1205000,15121500,0,-10323000,,-24105000,-24105000,791000,379057000,214776000,-16162000,1592000,198614000,9722000,-404039000,2366000,-902000,1458000,171029000,31067000,2256000,-91000,11648000,184717000,11919000,173297000,4000,20336000,24500,-4710500,-66000,-171000,-1712500,3500,-27346000,-63000,-25504500,835500,-33000,-602500,-1545000,3002500,-57500,153650000,en-US,US,EQUITY,True,Delayed Quote,USD,GENFIT S.A.,-0.0401538,187193664,-9.784173,15,America/New_York,EDT,-14400000,False,False,PREPRE,0,4,4.08,1630526403,-0.059999943,4.15,4.16,4.08,20154,NMS,us_market,0.98039126,1630531042,4.12,0.03999996,-1.449274,4.08 - 4.16,4.14,0.0,0.0,8,8,finmb_9683234,NasdaqGS,Genfit SA,EUR,10470,14342,0.5799999,0.16571426,3.5 - 7.19,-3.1100001,-0.4325452,3.5,7.19,-3.109,-0.417,3.7712,0.30879998,0.08188374,4.250681,-0.170681,1.13,,,7.19,3.5,3.7712,4.2507,10.47k,14.34k,45.75M,,43.73M,0.00%,1.76%,22.14k,1.72,,0.05%,9.4k,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,-999.09%,-19.05%,-298.13%,7.76M,0.20,-92.80%,7.76M,-73.95M,-101.22M,-3.1090,,171.03M,3.74,185.69M,,5.95,-0.42,-96.37M,-63.99M,Value,59120,Healthcare,130,10,8,"Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.",Loos,33 3 20 16 40 00,5,1609372800,1622505600,9,France,http://www.genfit.com,86400,9,Parc EurasantE,33 2 20 16 40 01,Biotechnology,"885, avenue EugEne AvinEe"
t-1,GNFT,-16953000,45750200,11115000,,-24239500,,-24105000,3872000,1205000,-13916500,-13916500,134500,-2964500,,,,-134500,1205000,15121500,0,-10323000,,-24105000,-24105000,791000,379057000,214776000,-16162000,1592000,198614000,9722000,-404039000,2366000,-902000,1458000,171029000,31067000,2256000,-91000,11648000,184717000,11919000,173297000,4000,20336000,24500,-4710500,-66000,-171000,-1712500,3500,-27346000,-63000,-25504500,835500,-33000,-602500,-1545000,3002500,-57500,153650000,en-US,US,EQUITY,True,Delayed Quote,USD,GENFIT S.A.,-0.0401538,187193664,-9.784173,15,America/New_York,EDT,-14400000,False,False,PREPRE,0,4,4.08,1630526403,-0.059999943,4.15,4.16,4.08,20154,NMS,us_market,0.98039126,1630531042,4.12,0.03999996,-1.449274,4.08 - 4.16,4.14,0.0,0.0,8,8,finmb_9683234,NasdaqGS,Genfit SA,EUR,10470,14342,0.5799999,0.16571426,3.5 - 7.19,-3.1100001,-0.4325452,3.5,7.19,-3.109,-0.417,3.7712,0.30879998,0.08188374,4.250681,-0.170681,1.13,,,7.19,3.5,3.7712,4.2507,10.47k,14.34k,45.75M,,43.73M,0.00%,1.76%,22.14k,1.72,,0.05%,9.4k,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,-999.09%,-19.05%,-298.13%,7.76M,0.20,-92.80%,7.76M,-73.95M,-101.22M,-3.1090,,171.03M,3.74,185.69M,,5.95,-0.42,-96.37M,-63.99M,Value,59120,Healthcare,130,10,8,"Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.",Loos,33 3 20 16 40 00,5,1609372800,1622505600,9,France,http://www.genfit.com,86400,9,Parc EurasantE,33 2 20 16 40 01,Biotechnology,"885, avenue EugEne AvinEe"
t-2,GNFT,30488000,45750200,18433500,,-26585000,,-26505500,8871000,2674000,-24838000,-24838000,207500,-2924000,,,,-79500,2674000,27512000,0,-1747000,,-26505500,-26505500,894000,378334000,224818000,31382000,2704000,256200000,9715000,-356017000,3010000,-650000,1595000,225721000,41706000,2406000,6000,15507000,238204000,8938000,170991000,5000,30083000,-24500,-1013000,-417000,-800500,-2415500,3500,-25513500,-63000,-22681000,789500,-33000,761500,-1615000,3207500,-392500,196498000,en-US,US,EQUITY,True,Delayed Quote,USD,GENFIT S.A.,-0.0401538,187193664,-9.784173,15,America/New_York,EDT,-14400000,False,False,PREPRE,0,4,4.08,1630526403,-0.059999943,4.15,4.16,4.08,20154,NMS,us_market,0.98039126,1630531042,4.12,0.03999996,-1.449274,4.08 - 4.16,4.14,0.0,0.0,8,8,finmb_9683234,NasdaqGS,Genfit SA,EUR,10470,14342,0.5799999,0.16571426,3.5 - 7.19,-3.1100001,-0.4325452,3.5,7.19,-3.109,-0.417,3.7712,0.30879998,0.08188374,4.250681,-0.170681,1.13,,,7.19,3.5,3.7712,4.2507,10.47k,14.34k,45.75M,,43.73M,0.00%,1.76%,22.14k,1.72,,0.05%,9.4k,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,-999.09%,-19.05%,-298.13%,7.76M,0.20,-92.80%,7.76M,-73.95M,-101.22M,-3.1090,,171.03M,3.74,185.69M,,5.95,-0.42,-96.37M,-63.99M,Value,59120,Healthcare,130,10,8,"Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.",Loos,33 3 20 16 40 00,5,1609372800,1622505600,9,France,http://www.genfit.com,86400,9,Parc EurasantE,33 2 20 16 40 01,Biotechnology,"885, avenue EugEne AvinEe"
t-3,GNFT,30488000,45750200,18433500,,-26585000,,-26505500,8871000,2674000,-24838000,-24838000,207500,-2924000,,,,-79500,2674000,27512000,0,-1747000,,-26505500,-26505500,894000,378334000,224818000,31382000,2704000,256200000,9715000,-356017000,3010000,-650000,1595000,225721000,41706000,2406000,6000,15507000,238204000,8938000,170991000,5000,30083000,-24500,-1013000,-417000,-800500,-2415500,3500,-25513500,-63000,-22681000,789500,-33000,761500,-1615000,3207500,-392500,196498000,en-US,US,EQUITY,True,Delayed Quote,USD,GENFIT S.A.,-0.0401538,187193664,-9.784173,15,America/New_York,EDT,-14400000,False,False,PREPRE,0,4,4.08,1630526403,-0.059999943,4.15,4.16,4.08,20154,NMS,us_market,0.98039126,1630531042,4.12,0.03999996,-1.449274,4.08 - 4.16,4.14,0.0,0.0,8,8,finmb_9683234,NasdaqGS,Genfit SA,EUR,10470,14342,0.5799999,0.16571426,3.5 - 7.19,-3.1100001,-0.4325452,3.5,7.19,-3.109,-0.417,3.7712,0.30879998,0.08188374,4.250681,-0.170681,1.13,,,7.19,3.5,3.7712,4.2507,10.47k,14.34k,45.75M,,43.73M,0.00%,1.76%,22.14k,1.72,,0.05%,9.4k,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,-999.09%,-19.05%,-298.13%,7.76M,0.20,-92.80%,7.76M,-73.95M,-101.22M,-3.1090,,171.03M,3.74,185.69M,,5.95,-0.42,-96.37M,-63.99M,Value,59120,Healthcare,130,10,8,"Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.",Loos,33 3 20 16 40 00,5,1609372800,1622505600,9,France,http://www.genfit.com,86400,9,Parc EurasantE,33 2 20 16 40 01,Biotechnology,"885, avenue EugEne AvinEe"
